Key insights
- Allogene Therapeutics reported positive interim Phase 2 ALPHA3 trial results for cema-cel in lymphoma, showing a higher rate of MRD negativity compared to the observation arm. Cema-cel was generally well-tolerated. Allogene has a strong cash position, but is burning through cash quickly. This news is slightly bullish for Allogene, but has limited impact on the broader US equity market.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced Monday interim results from its pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). The information is based on a statement from the company’s SEC filing.
The ALPHA3 trial is a randomized study designed to assess whether minimal residual disease (MRD)-guided intervention with cema-cel before relapse can eliminate residual disease and potentially prevent recurrence. The study uses Natera’s investigational CLARITY MRD assay to identify high-risk patients.
The interim futility analysis included the first 24 patients randomized in two study arms still open to enrollment, with 12 patients each in the cema-cel and observation arms. MRD was assessed at multiple timepoints, including Day 45 and Month 3.
At the protocol-defined cutoff, 58.3% (7 of 12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2 of 12) in the observation arm, a difference of 41.6 percentage points. At the first MRD assessment, plasma ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm, while the observation arm saw a median increase of 26.6%.
Safety data showed that cema-cel was generally well-tolerated. There were no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease in the cema-cel arm. Infection events were low grade and occurred in 16.7% of patients in both arms. Other neurologic events, such as headache and dizziness, were reported in 50% of the cema-cel arm and 8.3% of the observation arm, but none were grade 3 or higher.The biotech company maintains a solid financial position to support its clinical programs, with an InvestingPro Tip noting that Allogene holds more cash than debt on its balance sheet and a current ratio of 7.93. The company’s market capitalization stands at $663 million, though analysts note it is quickly burning through cash—typical for clinical-stage biotechs advancing pivotal trials.
Ten out of twelve patients who received cema-cel were managed entirely as outpatients after infusion. Two were briefly hospitalized for events deemed unrelated to cema-cel treatment.
The ALPHA3 trial is enrolling across more than 60 sites and aims to enroll approximately 220 patients, with study accrual expected to complete by the end of 2027. Interim and primary event-free survival analyses are anticipated in mid-2027 and mid-2028, respectively.
This report is based on a press release statement filed with the U.S. Securities and Exchange Commission.
In other recent news, Allogene Therapeutics reported its fourth-quarter 2025 earnings, exceeding expectations with an earnings per share of -$0.17 compared to the forecast of -$0.23. The company also projected a revenue forecast of $2.22 billion. Additionally, Allogene shared interim results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel in large B-cell lymphoma, with 58.3% of patients in the treatment arm achieving minimal residual disease negativity. Jefferies initiated coverage on Allogene with a buy rating and a price target of $6.00, highlighting the potential of its allogeneic cell therapies. Citizens reiterated its Market Outperform rating and set a $5.00 price target, citing pipeline progress and a discounted EPS and revenue multiple analysis. These developments reflect ongoing advancements and analyst confidence in Allogene’s therapeutic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.